JAK and IL-6 inhibitors outperform TNF inhibitors for activity limitation in rheumatoid arthritis
Specific Biologic Drugs Show Better Results for Rheumatoid Arthritis
This meta-analysis of 99 studies evaluated patient-reported outcomes (PROs) in patients with rheumatoid arthritis treated with b/tsDMARDs. T…
New analysis shows that certain types of biologic drugs may better reduce activity limits and improve mental health for people with rheumato…
Risk-optimized use of Janus kinase inhibitors in Japanese patients with rheumatoid arthritis depends on comorbidities
New evidence helps doctors choose safer arthritis treatments for seniors
This narrative review examines the safety and risk profile of Janus kinase inhibitors (JAKi) for rheumatoid arthritis specifically within th…
Doctors are moving toward personalized plans for rheumatoid arthritis, focusing on a patient's specific health risks rather than just their …
Biologic and targeted synthetic DMARDs show reassuring malignancy safety in inflammatory arthritides, but non-melanoma skin cancer risk rises with TNF inhibitors
Biologics for arthritis: Cancer risk appears low overall
This narrative review of biologic and targeted synthetic DMARDs in immune-mediated inflammatory arthritides finds most therapies have reassu…
Most biologic arthritis drugs don't raise overall cancer risk, but skin cancer risk may be higher with some.
Targeted therapies for psoriasis and psoriatic arthritis significantly alter lipid profiles across diverse patient populations
Psoriasis drugs change heart risk in surprising ways
A comprehensive meta-analysis of 24,575 patients reveals that targeted therapies for psoriasis and psoriatic arthritis consistently modify l…
Some common psoriasis drugs sharply raise cholesterol while others lower it, forcing doctors to rethink how they protect their patients’ hea…